You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

562 Results
Blog post
Dr. Leta Forbes, Medical OncologistProvincial Head, Systemic Treatment ProgramOntario Health (Cancer Care Ontario) Reactions to the injection of...
Sep 2019
Document
Oct 2019
Document
Oct 2019
Document
Oct 2019
Document
Oct 2019
Document
Oct 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab (Unfunded),
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Document
Dec 2019
Document
Jan 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
gemcitabine,
CISplatin,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2020
Document
Mar 2020
Guidelines and Advice
Status: Current
Version: 2
Dec 2021

Pages